Inventprise
Biotech company developing multivalent conjugate and other vaccine platforms with integrated R&D, analytical development, and automated cGMP manufacturing capabilities. Core programs include high-valent pneumococcal conjugate vaccines, Group B Streptococcus, Shigella, Klebsiella, microneedle (D-MAP) delivery, and an mRNA/LNP vaccine platform. Facilities and programs support early-stage through commercial manufacturing and regulatory submissions.
Industries
Nr. of Employees
medium (51-250)
Inventprise
Patents
Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
US-12734229-B2
View DetailsMultivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
US-12053515-B2
View Details
Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
US-12734229-B2
View DetailsMultivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
US-12053515-B2
View DetailsProducts
25-valent pneumococcal conjugate vaccine (PCV-25)
High-valent pneumococcal conjugate vaccine candidate intended for pediatric and adult immunization to prevent pneumococcal disease and otitis media.
Hexavalent Group B Streptococcus conjugate vaccine (GBS-06)
Maternal immunization candidate covering multiple GBS serotypes to prevent neonatal sepsis, meningitis and stillbirths.
Quadrivalent Shigella conjugate vaccine (Shigella-04)
Multivalent conjugate candidate to reduce morbidity and mortality from shigellosis and potentially decrease antibiotic use.
Klebsiella conjugate vaccine
Vaccine candidate targeting Klebsiella pneumoniae to reduce neonatal and hospital-acquired infections and mitigate antimicrobial resistance burden.
Dissolvable microarray patch (D-MAP) delivery platform
Microneedle patch delivery technology designed to deliver multiple antigens with small storage footprint and potential thermostability.
mRNA vaccine platform and RSV mRNA candidate
Platform for high-yield mRNA expression and LNP encapsulation to produce mRNA vaccines in a GMP setting; candidate focused on RSV.
25-valent pneumococcal conjugate vaccine (PCV-25)
High-valent pneumococcal conjugate vaccine candidate intended for pediatric and adult immunization to prevent pneumococcal disease and otitis media.
Hexavalent Group B Streptococcus conjugate vaccine (GBS-06)
Maternal immunization candidate covering multiple GBS serotypes to prevent neonatal sepsis, meningitis and stillbirths.
Quadrivalent Shigella conjugate vaccine (Shigella-04)
Multivalent conjugate candidate to reduce morbidity and mortality from shigellosis and potentially decrease antibiotic use.
Klebsiella conjugate vaccine
Vaccine candidate targeting Klebsiella pneumoniae to reduce neonatal and hospital-acquired infections and mitigate antimicrobial resistance burden.
Dissolvable microarray patch (D-MAP) delivery platform
Microneedle patch delivery technology designed to deliver multiple antigens with small storage footprint and potential thermostability.
mRNA vaccine platform and RSV mRNA candidate
Platform for high-yield mRNA expression and LNP encapsulation to produce mRNA vaccines in a GMP setting; candidate focused on RSV.
Services
Optimization and scale-up of protein and conjugate vaccine processes including fermentation, purification, conjugation and formulation.
cGMP manufacturing services across development and commercial scales with automated equipment, cleanrooms, and 24/7 monitoring for chain of identity/custody.
Quality system design, regulatory strategy support, and validated automated systems to support regulatory filings and commercialization.
Design and implementation of manufacturing automation aligned with ISA-95/ISA-88 and Pharma 4.0 principles to enable continuous manufacturing and observability.
Optimization and scale-up of protein and conjugate vaccine processes including fermentation, purification, conjugation and formulation.
cGMP manufacturing services across development and commercial scales with automated equipment, cleanrooms, and 24/7 monitoring for chain of identity/custody.
Quality system design, regulatory strategy support, and validated automated systems to support regulatory filings and commercialization.
Design and implementation of manufacturing automation aligned with ISA-95/ISA-88 and Pharma 4.0 principles to enable continuous manufacturing and observability.
Expertise Areas
- Conjugate vaccine development
- Clinical trial manufacturing and support
- cGMP biologics manufacturing (automated)
- Process development and scale-up for vaccines
Key Technologies
- PEG linker-based conjugation chemistry
- Polysaccharide activation (CDAP)
- Carrier protein derivatization
- Lipid nanoparticle (LNP) encapsulation
News & Updates
Press release announcing positive interim Phase 1/2 results for a hexavalent maternal Group B Streptococcus conjugate vaccine candidate.
Press release summarizing publication of conjugate COVID-19 vaccine study results in the journal Vaccine.
Announcement of selection of an mRNA production technology to advance mRNA vaccine development.
Announcement of opening a large-scale automated cGMP manufacturing facility intended to produce vaccine drug product at commercial scale.
Commissioned a 70,000 sq. ft. automated cGMP manufacturing site with ISO 5/7/8 cleanrooms and supporting infrastructure.
Peer-reviewed publication reporting results from a conjugate vaccine study (SARS-CoV-2 conjugate vaccine) in the journal Vaccine.
Press release announcing positive interim Phase 1/2 results for a hexavalent maternal Group B Streptococcus conjugate vaccine candidate.
Press release summarizing publication of conjugate COVID-19 vaccine study results in the journal Vaccine.
Announcement of selection of an mRNA production technology to advance mRNA vaccine development.
Announcement of opening a large-scale automated cGMP manufacturing facility intended to produce vaccine drug product at commercial scale.
Commissioned a 70,000 sq. ft. automated cGMP manufacturing site with ISO 5/7/8 cleanrooms and supporting infrastructure.
Peer-reviewed publication reporting results from a conjugate vaccine study (SARS-CoV-2 conjugate vaccine) in the journal Vaccine.